Jose Carmona - 31 Jan 2022 Form 4 Insider Report for Rubius Therapeutics, Inc.

Role
Chief Financial Officer
Signature
/s/ Joanne M. Protano, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
31 Jan 2022
Net transactions value
$0
Form type
4
Filing time
01 Feb 2022, 20:20:24 UTC
Next filing
02 Jan 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RUBY Stock Option (Right to Buy) Award $0 +143,750 $0.000000 143,750 31 Jan 2022 Common Stock 143,750 $6.75 Direct F1
transaction RUBY Restricted Stock Units Award $0 +34,500 $0.000000 34,500 31 Jan 2022 Common Stock 34,500 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of this option shall vest on January 31, 2023, then in 12 equal quarterly installments thereafter.
F2 Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F3 The shares underlying the restricted stock units vest in four equal annual installments beginning on January 31, 2023.